EPOK Therapeutics

Executive Summary

EPOK Therapeutics is a San Diego-based preclinical biotechnology company specializing in the development of engineered agonist and antagonist antibodies. Founded in 2023, the company aims to address key limitations of conventional antibody therapeutics by reducing off-target activity, enhancing safety profiles, and optimizing dosing regimens and production efficiency. Leveraging protein engineering and rational design, EPOK's platform seeks to create next-generation biologics with improved therapeutic windows. As a private, early-stage company with no disclosed funding or disclosed pipeline candidates, EPOK faces significant development and regulatory risks typical of preclinical biotechs. Its success will depend on advancing lead candidates to IND, securing partnerships or financing, and demonstrating differentiation from established antibody platforms. The company's location in San Diego provides access to a strong biotech ecosystem.

Upcoming Catalysts (preview)

• TBDLead program selection and IND-enabling studies initiation30% success
• TBDSeries A financing or strategic partnership40% success
• TBDPublication of preclinical proof-of-concept data50% success